Promising new combo tackles tough bone cancer

NCT ID NCT04067115

Completed Disease control Sponsor: Sarcoma Alliance for Research through Collaboration Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two drugs, trabectedin and irinotecan, in 37 people with a type of bone cancer called Ewing sarcoma that had come back or not responded to other treatments. The goal was to find a safe dose and see if the combination could shrink tumors. Participants also received a special PET scan to help measure the treatment's effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EWING SARCOMA

Contacts and locations

Locations

Boston Children's Hospital / Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Children's Hospital of Los Angeles

Los Angeles, California, 90027, United States
Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
National Cancer Institute

Bethesda, Maryland, 20892, United States
University of Michigan

Ann Arbor, Michigan, 48106, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.